Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrigâ€™s disease; progressive multiple sclerosis (PMS); Alzheimerâ€™s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. It has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The Company's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.

Employees

Sector

Biotechnology & Medical Research

More about the company

08-14	Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-28	Brainstorm Cell Therapeutics Inc. Announces Executive and Board Changes	CI

Market Cap	9.93M 8.66M 8.18M 7.43M 13.91M 953M 13.97M 97.95M 37.8M 484M 37.31M 36.48M 1.56B	P/E 2026 *	-0.99x	P/E 2027 *	-0.88x
Enterprise Value	9.93M 8.66M 8.18M 7.43M 13.91M 953M 13.97M 97.95M 37.8M 484M 37.31M 36.48M 1.56B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	88.82%	Yield 2026 *	-	Yield 2027 *	-

08-14	Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-28	Brainstorm Cell Therapeutics Inc. Announces Executive and Board Changes	CI
05-29	BrainStorm Cell Therapeutics Inc. Appoints Peter J. Pitts to Board of Directors, Effective May 29, 2026	CI
05-15	Brainstorm Cell Therapeutics announces first quarter 2026 financial results and provides corporate update	RE
05-15	Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-10	Brainstorm Cell Therapeutics Inc. announced that it has received $0.2 million in funding	CI
05-03	Brainstorm Cell Therapeutics Inc. announced that it expects to receive $0.2 million in funding	CI
03-31	Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	Brainstorm Cell Therapeutics Inc. Auditor Raises 'Going Concern' Doubt	CI
02-26	Brainstorm Cell Therapeutics Inc. announced that it has received $2 million in funding	CI
02-23	Brainstorm Cell Therapeutics Inc. announced that it expects to receive $1 million in funding	CI
02-20	Brainstorm Cell Therapeutics announces $1 million strategic financing at premium to market	RE
02-08	Brainstorm Cell Therapeutics Inc. announced that it expects to receive $1 million in funding	CI

25-05-19	Top Midday Gainers	MT
24-07-11	Maxim Upgrades Brainstorm Cell Therapeutics to Buy From Hold, Price Target is $2	MT
23-09-28	Maxim Downgrades Brainstorm Cell Therapeutics to Hold From Buy	MT
23-03-31	Maxim Group Adjusts Price Target on Brainstorm Cell Therapeutics to $10 From $5, Maintains Buy Rating	MT
21-02-05	Brainstorm Cell Therapeutics : Maxim Group Upgrades Brainstorm Cell Therapeutics to Buy From Hold	MT

08-24	BrainStorm Executive Leadership to Participate in DUPHAT 2026; Executive Chairman Peter J. Pitts Invited to Deliver Two Keynote Addresses and Moderate Panel Sessions	PR
08-14	BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update	PR
07-28	BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman	PR
06-02	BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine	PR
05-29	BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors	AQ

Brainstorm Cell Therapeutics Inc Stock OTC Bulletin Board

Stocks

US10501E2019

Biotechnology & Medical Research

Valuation: Brainstorm Cell Therapeutics Inc

Latest news: Brainstorm Cell Therapeutics Inc

Analysts' recommendations: Brainstorm Cell Therapeutics Inc

Press Releases: Brainstorm Cell Therapeutics Inc

News in other languages: Brainstorm Cell Therapeutics Inc

Managers and Directors: Brainstorm Cell Therapeutics Inc

Other Biotechnology & Medical Research

Financials

Company Profile

23-09-26	USA-Les valeurs à suivre à Wall Street (actualisé)
20-10-23	Catalent et BrainStorm Cell Therapeutics annoncent un partenariat pour la conception de la plateforme de thérapie par cellules souches mésenchymateuses NurOwn®

Manager	Title	Age	Since
Chaim Lebovits CEO	Chief Executive Officer	55	2013-07-31
Peter Pitts LAW	General Counsel	67	2026-07-23
Alla Patlis DFI	Director of Finance/CFO	39	2021-08-30

Director	Title	Age	Since
Irit Arbel CHM	Chairman	66	2014-04-24
Uri Yablonka BRD	Director/Board Member	49	2014-06-05
Anthony Polverino BRD	Director/Board Member	63	2018-02-04

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+1.01%	+3.26%	+2.00%	+29.39%	46.28B
IQVIA HOLDINGS INC.	-1.12%	+1.78%	+42.30%	+29.70%	43.85B
REVOLUTION MEDICINES, INC.	-3.04%	-6.29%	+338.56%	+542.28%	40.93B
BEONE MEDICINES AG	-0.74%	+1.25%	+4.92%	+81.93%	39.89B
CELLTRION, INC.	-0.50%	+0.67%	+10.29%	+41.57%	29.5B
MEDPACE HOLDINGS, INC.	-0.46%	+4.22%	+22.81%	+140.41%	17.09B
ASCENDIS PHARMA A/S	-0.97%	-10.17%	-	-	15.55B
EUROFINS SCIENTIFIC SE	+1.05%	+6.98%	+23.17%	+39.65%	15.22B
TEMPUS AI, INC.	-3.14%	+31.91%	-11.79%	-	14.05B
Average	-0.89%	+3.76%	+54.03%	+129.28%	29.15B
Weighted average by Cap.	-0.86%	+1.87%	+68.40%	+139.00%

	2026 *	2027 *
Net sales	-	-
Net income	-13.78M -12.01M -11.34M -10.3M -19.3M -1.32B -19.38M -136M -52.43M -672M -51.75M -50.6M -2.16B	-29.97M -26.13M -24.68M -22.41M -41.98M -2.88B -42.16M -296M -114M -1.46B -113M -110M -4.7B
Net Debt	-	-

End-of-day quote OTC Bulletin Board
- ^USD	-